

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal61ltxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	May 12 EXTEND option available in structure searching
NEWS	4	May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in CPlus
NEWS	6	May 27 CPlus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12 BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02 CPlus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02 STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02 The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04 Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	16	AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	17	AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	18	SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS	19	SEP 01 New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	20	SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS EXPRESS		JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

10/635,433

Thomas McKenzie

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:21:03 ON 08 SEP 2004

=> file reg

FILE 'REGISTRY' ENTERED AT 17:21:13 ON 08 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2004 HIGHEST RN 741217-26-5

DICTIONARY FILE UPDATES: 7 SEP 2004 HIGHEST RN 741217-26-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004



Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10635433.str



chain nodes :

19 20 21 22 23 24 26 27 28

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

4-27 10-19 13-19 17-24 17-26 18-20 20-21 20-22 22-23 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18

exact/norm bonds :

4-27 10-19 13-14 13-18 13-19 14-15 15-16 16-17 17-18 17-24 17-26 18-20
20-21 20-22 22-23 27-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:H,CH3,OH

G2:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 26:CLASS 27:CLASS 28:CLASS
30:CLASS

10/635,433

Thomas McKenzie

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 17:21:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS
SEARCH TIME: 00.00.01

5 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1


=> d scan

L2 5 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN 1-Piperazinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-2-methyl-4-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, ethyl ester, (2S,3R)- (9CI)

MF C23 H29 N3 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full; file caplus; s l3

FULL SEARCH INITIATED 17:22:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 125 TO ITERATE

100.0% PROCESSED 125 ITERATIONS
SEARCH TIME: 00.00.01

72 ANSWERS

L3 72 SEA SSS FUL L1

FILE 'CAPLUS' ENTERED AT 17:22:28 ON 08 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Sep 2004 VOL 141 ISS 11
FILE LAST UPDATED: 7 Sep 2004 (20040907/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

L4 6 L3

=> sort py l4
SORT ENTIRE ANSWER SET? (Y)/N:.
PROCESSING COMPLETED FOR L4
L5 6 SORT L4 PY

=> d 1-5 cbib pi fhitr

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

2000:133663 Document No. 132:166133 Preparation of hydroxy pipecolate hydroxamic acid derivatives as MMP inhibitors. McClure, Kim Francis; Noe, Mark Carl; Letavic, Michael Anthony; Chupak, Louis Stanley (Pfizer Products Inc., USA). PCT Int. Appl. WO 2000009485 A1 20000224, 98 pp.
DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English).
CODEN: PIXXD2. APPLICATION: WO 1999-IB1388 19990805. PRIORITY: US 1998-96232 19980812.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000009485	A1	20000224	WO 1999-IB1388	19990805
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			


CA 2340202	AA	20000224	CA 1999-2340202	19990805
AU 9949247	A1	20000306	AU 1999-49247	19990805
AU 766366	B2	20031016		
BR 9912909	A	20010508	BR 1999-12909	19990805
EP 1104403	A1	20010606	EP 1999-933076	19990805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100474	T2	20010621	TR 2001-200100474	19990805
EE 200100086	A	20020815	EE 2001-86	19990805
NZ 509296	A	20031031	NZ 1999-509296	19990805
US 6329397	B1	20011211	US 1999-372946	19990812
ZA 2001001042	A	20021007	ZA 2001-1042	20010207
HR 2001000098	A1	20020228	HR 2001-98	20010208
NO 2001000686	A	20010409	NO 2001-686	20010209
BG 105323	A	20011031	BG 2001-105323	20010309
US 2003008901	A1	20030109	US 2001-8943	20011203

IT 258860-60-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxy pipercolate hydroxamic acid derivs. as MMP inhibitors)

RN 258860-60-5 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

2001:167662 Document No. 134:207829 Preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivatives as selective inhibitors of aggrecanase in osteoarthritis treatment. Noe, Mark Carl; Letavic, Michael A.; Hawkins, Joel M. (Pfizer Products Inc., USA). Eur. Pat. Appl. EP 1081137 A1 20010307, 65 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 2000-306745 20000808. PRIORITY: US 1999-PV148464 19990812.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	EP 1081137	A1	20010307	EP 2000-306745	20000808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	JP 2001114765	A2	20010424	JP 2000-243139	20000810
	JP 2003040800	A2	20030213	JP 2002-210977	20000810
	BR 2000003568	A	20010403	BR 2000-3568	20000814
	JP 2004168786	A2	20040617	JP 2004-27695	20040204

IT 329040-86-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and
-piperazine derivs. as selective inhibitors of aggrecanase in
osteoarthritis treatment)

RN 329040-86-0 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(2,4-dichlorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

2003:3568 Document No. 138:396061 Effect of tumor necrosis factor- α converting enzyme (TACE) and metalloprotease inhibitor on amyloid precursor protein metabolism in human neurons. Blacker, Megan; Noe, Mark C.; Carty, Thomas J.; Goodyer, Cynthia G.; LeBlanc, Andrea C. (The Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Montreal, QC, Can.). Journal of Neurochemistry, 83(6), 1349-1357 (English) 2002. CODEN: JONRA9. ISSN: 0022-3042. Publisher: Blackwell Science Ltd..

IT 530135-92-3, CP 661631


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TACE and metalloprotease inhibitor CP-661,631 prevents amyloid precursor protein secretion but does not increase amyloid β levels)

RN 530135-92-3 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

2003:971264 Document No. 140:23252 Neuroprotective and neurogenerative effects of the long-term expression of TNF alpha in the substantia nigra and a new animal model for Parkinson's disease. Pitossi, Fernando Juan; Eisel, Ulrich Lothar Maria (Argent.). U.S. Pat. Appl. Publ. US 2003228276 A1 20031211, 18 pp. (English). CODEN: USXXCO. APPLICATION: US 2003-410012 20030409. PRIORITY: US 2002-PV370974 20020409.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003228276	A1	20031211	US 2003-410012	20030409

IT 530135-92-3, CP 661631


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neuroprotective and neurogenerative effects of long-term expression of TNF alpha in substantia nigra)

RN 530135-92-3 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

2003:689649 Document No. 139:292229 Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-α converting enzyme inhibitors. Letavic, Michael A.; Barberia, John T.; Carty, Thomas J.; Hardink, Joel R.; Liras, Jennifer; Lopresti-Morrow, Lori L.; Mitchell, Peter G.; Noe, Mark C.; Reeves, Lisa M.; Snow, Sheri L.; Stam, Ethan J.; Sweeney, Francis J.; Vaughn, Marcie L.; Yu, Chul H. (Groton Laboratories, Pfizer Global Research and Development, Groton, CT, 06340, USA). Bioorganic & Medicinal Chemistry Letters, 13(19), 3243-3246 (English) 2003. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT 139:292229. Publisher: Elsevier Science B.V..


IT 609816-96-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of piperazine-based dual MMP-13 and TNF-α converting enzyme inhibitors)

RN 609816-96-8 CAPLUS

CN 2-Piperazinecarboxamide, N-hydroxy-3-methyl-1-[[4-(phenylmethoxy)phenyl]sulfonyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d 6 cbib pi fhitstr

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

2004:344241 Document No. 141:64401 Receptor Flexibility in the in Silico Screening of Reagents in the S1' Pocket of Human Collagenase. Kaellblad, Per; Todorov, Nikolay P.; Willems, Henriette M. G.; Alberts, Ian L. (De Novo Pharmaceuticals Ltd., Cambridge, CB4 9ZR, UK). Journal of Medicinal Chemistry, 47(11), 2761-2767 (English) 2004. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.


IT 709614-44-8

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(receptor flexibility in silico screening of reagents in S1' pocket of human collagenase)

RN 709614-44-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



=> d 1-2 cbib pi hitstr


L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

2000:133663 Document No. 132:166133 Preparation of hydroxy pipercolate hydroxamic acid derivatives as MMP inhibitors. McClure, Kim Francis; Noe, Mark Carl; Letavic, Michael Anthony; Chupak, Louis Stanley (Pfizer Products Inc., USA). PCT Int. Appl. WO 2000009485 A1 20000224, 98 pp.

DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-IB1388 19990805. PRIORITY: US

1998-96232 19980812.


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000009485	A1	20000224	WO 1999-IB1388	19990805
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2340202	AA	20000224	CA 1999-2340202	19990805
AU 9949247	A1	20000306	AU 1999-49247	19990805
AU 766366	B2	20031016		
BR 9912909	A	20010508	BR 1999-12909	19990805
EP 1104403	A1	20010606	EP 1999-933076	19990805
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR 200100474	T2	20010621	TR 2001-200100474	19990805
EE 200100086	A	20020815	EE 2001-86	19990805
NZ 509296	A	20031031	NZ 1999-509296	19990805
US 6329397	B1	20011211	US 1999-372946	19990812
ZA 2001001042	A	20021007	ZA 2001-1042	20010207
HR 2001000098	A1	20020228	HR 2001-98	20010208
NO 2001000686	A	20010409	NO 2001-686	20010209
BG 105323	A	20011031	BG 2001-105323	20010309
US 2003008901	A1	20030109	US 2001-8943	20011203
IT 258860-60-5P 258860-83-2P 258860-84-3P 258861-36-8P 258861-37-9P				
RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of hydroxy pipercolate hydroxamic acid derivs. as MMP inhibitors)			
RN 258860-60-5	CAPLUS			
CN	2-Piperidinecarboxamide, 1-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)			



RN 258860-83-2 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258860-84-3 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258861-36-8 CAPLUS

CN 2-Piperidinecarboxamide, N,5-dihydroxy-3-methyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (2R,3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258861-37-9 CAPLUS

CN 2-Piperidinecarboxamide, N,5-dihydroxy-3-methyl-1-[[4-[(2-methylethyl)phenyl]methoxy]phenyl]sulfonyl]-, (2R,3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 258861-52-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxy piperidate hydroxamic acid derivs. as MMP inhibitors)

RN 258861-52-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl]-3-hydroxy-3-methyl-N-(2-propenyloxy)- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

2001:167662 Document No. 134:207829 Preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivatives as selective inhibitors of aggrecanase in osteoarthritis treatment. Noe, Mark Carl; Letavic, Michael A.; Hawkins, Joel M. (Pfizer Products Inc., USA). Eur. Pat. Appl. EP 1081137 A1 20010307, 65 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 2000-306745 20000808. PRIORITY: US 1999-PV148464 19990812.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1081137	A1	20010307	EP 2000-306745	20000808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001114765	A2	20010424	JP 2000-243139	20000810
JP 2003040800	A2	20030213	JP 2002-210977	20000810
BR 2000003568	A	20010403	BR 2000-3568	20000814
JP 2004168786	A2	20040617	JP 2004-27695	20040204

IT 329040-86-0P 329040-87-1P 329040-88-2P
329040-89-3P 329040-90-6P 329040-91-7P
329040-92-8P 329040-93-9P 329040-94-0P
329040-95-1P 329040-96-2P 329040-97-3P
329040-98-4P 329040-99-5P 329041-00-1P
329041-01-2P 329041-02-3P 329041-03-4P
329041-04-5P 329041-05-6P 329041-06-7P


329041-07-8P 329041-08-9P 329041-09-0P
 329041-10-3P 329041-16-9P 329041-31-8P
 329041-47-6P 329041-48-7P 329041-50-1P
 329041-51-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivs. as selective inhibitors of aggrecanase in osteoarthritis treatment)

RN 329040-86-0 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(2,4-dichlorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-87-1 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(2,4-dichlorophenyl)methoxy]phenyl]sulfonyl]-N,5-dihydroxy-3,3-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-88-2 CAPLUS

CN 2-Piperazinecarboxamide, 4-(aminoacetyl)-N-hydroxy-3-methyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-89-3 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-[(4-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-3-methyl-5-oxo-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-90-6 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[[4-[(2-ethylphenyl)methoxy]phenyl]sulfonyl]-N3-hydroxy-N1,2-dimethyl-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-91-7 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-92-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonyl]-N,5-dihydroxy-3,3-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/635,433

Thomas McKenzie

RN 329040-93-9 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[[4-[(5-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N3-hydroxy-N1,2-dimethyl-, (2S,3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-94-0 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-95-1 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-chloro-2-fluorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-96-2 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl]-N,5-dihydroxy-3,3-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-97-3 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-[(5-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-3-methyl-5-oxo-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-98-4 CAPLUS

CN 2-Piperidinecarboxamide, N,3-dihydroxy-3-methyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329040-99-5 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(4-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N,5-dihydroxy-3,3-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-00-1 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(3-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N,5-dihydroxy-3,3-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-01-2 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-[(2-fluorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329041-02-3 CAPLUS
 CN 2-Piperidinecarboxamide, 1-[[4-[(2-chlorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329041-03-4 CAPLUS
 CN 2-Piperidinecarboxamide, 1-[[4-[(3-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 329041-04-5 CAPLUS
 CN 2-Piperidinecarboxamide, 1-[[4-[(5-chloro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N,5-dihydroxy-3,3-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-05-6 CAPLUS

CN 2-Piperidinecarboxamide, N,3-dihydroxy-3-methyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-06-7 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(2,4-difluorophenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-07-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(5-chloro-2-fluorophenyl)methoxy]phenyl]sulfonyl]-N,5-dihydroxy-3,3-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-08-9 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(5-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N,3-dihydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-09-0 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[(2-bromophenyl)methoxy]phenyl]sulfonyl]-N,5-dihydroxy-3,3-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-10-3 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[[4-[(2,4-difluorophenyl)methoxy]phenyl]sulfonyl]-N3-hydroxy-N1,2-dimethyl-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-16-9 CAPLUS

CN 2-Piperidinecarboxamide, N,3-dihydroxy-3-methyl-1-[[4-(phenylmethoxy)phenyl]sulfonyl]-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 329041-31-8 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-[[5-fluoro-2-(trifluoromethyl)phenyl]methoxy]phenyl]sulfonyl]-N,5-dihydroxy-3,3-dimethyl-, (2R,5R)- (9CI) (CA INDEX NAME)

10/635,433

Thomas McKenzie

NAME)


Absolute stereochemistry.



RN 329041-47-6 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[[4-[(5-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N1,2-dimethyl-N3-(2-propenyloxy)-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-48-7 CAPLUS

CN 2-Piperazinecarboxamide, 4-(aminoacetyl)-1-[[4-[(5-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-50-1 CAPLUS

CN Carbamic acid, [2-[(2R,3R)-3-[(hydroxyamino)carbonyl]-2-methyl-4-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-1-piperazinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329041-51-2 CAPLUS

CN 2-Piperazinecarboxamide, 4-(aminoacetyl)-1-[[4-[(2-ethylphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-3-methyl-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 329041-49-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivs. as selective inhibitors of aggrecanase in osteoarthritis treatment)

RN 329041-49-8 CAPLUS

CN 2-Piperazinecarboxamide, 4-(aminoacetyl)-1-[[4-[(5-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-3-methyl-N-(2-propenyloxy)-, (2R,3R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:.

STN INTERNATIONAL LOGOFF AT 17:25:31 ON 08 SEP 2004

